Your browser doesn't support javascript.
loading
Utility of 5-ALA for fluorescence-guided resection of brain metastases: a systematic review.
Shah, Harshal A; Leskinen, Sandra; Khilji, Hamza; Narayan, Vinayak; Ben-Shalom, Netanel; D'Amico, Randy S.
Afiliação
  • Shah HA; Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA. hshah5@northwell.edu.
  • Leskinen S; State University of New York Downstate Medical Center, Brooklyn, NY, USA.
  • Khilji H; State University of New York Downstate Medical Center, Brooklyn, NY, USA.
  • Narayan V; Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.
  • Ben-Shalom N; Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.
  • D'Amico RS; Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.
J Neurooncol ; 160(3): 669-675, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36370294
ABSTRACT

PURPOSE:

5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas. However, literature regarding 5-ALA-guided resection for brain metastases is limited. We conducted a systematic review to evaluate the efficacy of 5-ALA fluorescence for resection of metastatic brain tumors.

METHODS:

PubMed was queried for studies involving 5-ALA and brain metastases, and results were screened following PRISMA guidelines. Articles related to 5-ALA and brain metastasis were further assessed based on inclusion and exclusion criteria and results were analyzed for 5-ALA fluorescence rates stratified by tumor primary sites and histological subtypes.

RESULTS:

Of 421 identified search results, 10 studies were included and a total of 631 patients analyzed. Of these studies, 60% were retrospective in design. The reported rates of 5-ALA fluorescence in included brain metastases ranged from 27.6 to 86.9%, with variability across and within tumor types. No studies concluded improved operative outcomes or survival outcomes related to 5-ALA use.

CONCLUSIONS:

Current studies regarding 5-ALA fluorescence in brain metastases are limited and do not confirm efficacy for improving extent of resection or post-operative survival. Fluorescence is variable across and within tumor types. Further studies are necessary to evaluate whether specific tumors may benefit from 5-ALA FGS or if changes in delivery protocols or fluorescence quantification may affect intraoperative utility.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Cirurgia Assistida por Computador / Glioma Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Cirurgia Assistida por Computador / Glioma Idioma: En Ano de publicação: 2022 Tipo de documento: Article